News and Trends 27 Jan 2023 EMA accepts Marketing Authorization Application for lecanemab to treat early Alzheimer’s disease …beta (Aβ) protofibril antibody, for the treatment of early Alzheimer’s disease (mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD dementia) with confirmed amyloid pathology, for review following… January 27, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 German Drug to Stop the Progression of Alzheimer’s Enters Phase IIb Probiodrug is ready to start a Phase IIb trial with an Alzheimer’s drug that prevents the formation of Aβ plaques before the disease progresses. The German biotech Probiodrug is getting… October 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2023 Researchers’ mutation discovery offers new Alzheimer’s hope Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting tens of millions of people worldwide, and it is the most common cause of dementia. Early-onset AD is typically associated with… May 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Aug 2017 German Scientists Publish New Mechanism of Action Against Alzheimer’s Researchers at the German biotech Probiodrug have published today the detailed mechanism of action of a drug that might succeed in treating Alzheimer’s where many others have failed. Probiodrug is… August 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2017 Swiss Biotech Gets €12M as its Alzheimer’s Candidate Enters Phase II AC Immune’s Anti-Tau antibody for the treatment of Alzheimer’s disease has reached Phase II, prompting milestone payments from Genentech. Today, the first patient in a Phase II trial was dosed… November 2, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 2 Apr 2025 Beyond amyloid: The search for the next big thing in Alzheimer’s treatment Alzheimer’s disease affects more than 55 million people worldwide — a number expected to nearly triple by 2050. Despite decades of research and billions invested, Alzheimer’s remains without a cure,… April 2, 2025 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2016 Evotec closes the year partnering with Celgene to treat Alzheimer’s …into solid tumors, inflammatory diseases, and now neurodegenerative conditions, which will include Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis (ALS) among others. With these ambitious targets, both Celgene and Evotec could… December 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 Liquid-interface assisted SERS could lead to earlier detection of Alzheimer’s …of virus infection and Alzheimer’s. SERS, based on an optical near-field effect induced by the surface plasmon of noble metal nanoparticles or nanostructures excited by laser radiation, amplifies the Raman… September 12, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug Tiziana Life Sciences Ltd. says it plans to submit an investigational new drug (IND) application for a phase 1 trial of intranasal foralumab in Alzheimer’s disease patients. It comes after… October 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 1 Nov 2024 Can AI cure Alzheimer’s disease? …tools help tackle another formidable challenge of modern biotech, Alzheimer’s disease. “Alzheimer’s is an incredibly complex disease with numerous factors at play. You have the buildup of amyloid plaques, tau… November 1, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 10 Feb 2025 Monoclonal antibodies: are they the key to treating Alzheimer’s disease? …Nearly 7 million people in the U.S. have Alzheimer’s disease, according to the Alzheimer’s Association. While 73% of people with Alzheimer’s disease are aged 75 and older, there is a… February 10, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2017 Allergan Takes to the Clinic a New Alzheimer’s Drug from a €3Bn Deal Allergan’s partner Heptares Therapeutics has dosed the first patient with a GPCR drug to treat major symptoms of Alzheimer’s disease. A year ago, Allergan signed a massive deal of up… September 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email